文献速递血栓与止血

血友病性关节病:当前认识与未来展望

Hemophilic arthropathy: Current knowledge and future perspectives.
PubMed 文献 · J Thromb Haemost · 2021-07-27

本文综述了血友病A和B中复发性关节出血导致血友病性关节病的机制与管理现状。预防性凝血因子替代治疗及非替代疗法(如艾美珠单抗皮下注射)改善了治疗依从性和关节保护,但慢性关节病仍是重要问题。即时超声改善了急性关节出血和早期关节病的诊断与监测,未来需深入研究发病机制以开发靶向治疗。

要点

  • 预防出血是维持关节健康的关键,因缺乏特异性治疗来减轻血液诱导的滑膜炎。
  • 延长半衰期凝血因子浓缩物及非替代疗法(如艾美珠单抗)提高了治疗依从性和关节保护。
  • 即时超声有助于诊断急性关节出血和早期血友病性关节病,并监测关节损伤进展。

核心结论

  • 尽管预防性治疗和非替代疗法取得进展,慢性血友病性关节病仍是重要临床问题。
  • 预防出血是维持关节健康的核心策略,因缺乏特异性治疗来减轻血液诱导的滑膜炎。
  • 需进一步研究血友病性关节病的发病机制以开发更靶向的治疗。

研究设计与样本

  • 综述,总结血友病性关节病的当前知识和未来展望。

主要发现

  • 复发性关节出血(关节积血)是重型血友病最常见的临床表现。
  • 即使亚临床关节积血,若未适当管理,也可导致血友病性关节病,特征为关节重塑、慢性疼痛和生活质量下降,最终需关节置换。
  • 延长半衰期重组凝血因子预防性替代治疗通过减少静脉注射负担显著改善患者生活质量。
  • 非替代疗法如皮下注射艾美珠单抗改善了治疗依从性,并加强对血友病A患者的保护。
  • 即时超声成像改善了急性关节积血和早期血友病性关节病的诊断,并允许更好地监测进行性关节损伤。

临床怎么用

  • 患者管理应基于每个患者关节病发病和进展的风险因素。
  • 所有患者应在综合血友病治疗中心由血液科、风湿科、骨科和物理治疗师组成的多学科团队协作照护。

局限性

  • 缺乏特异性治疗来减少血液诱导的滑膜炎。
  • 尽管有先进治疗,慢性关节病仍是显著问题。
  • 需要进一步研究疾病 underlying 机制以开发更靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX. Recurrent joint bleeding (hemarthrosis) is the most frequent clinical manifestation of severe hemophilia. Unless appropriately managed, even subclinical hemarthrosis can lead to the development of hemophilic arthropathy, a disabling condition characterized by joint remodelling, chronic pain, and a reduced quality of life, and eventually requires joint replacement. Given the lack of specific treatments to reduce blood-induced synovitis, the prevention of bleeding is pivotal to the maintenance of joint health. Prophylactic coagulation factor replacement therapy using extended half-life recombinant drugs has significantly improved patients' quality of life by reducing the burden of intravenous injections, and the more recent introduction of nonreplacement therapies such as subcutaneous emicizumab injections has improved treatment adherence and led to the greater protection of patients with hemophilia A. However, despite these advances, chronic arthropathy is still a significant problem. The introduction of point-of-care ultrasound imaging has improved the diagnosis of acute hemarthrosis and early hemophilic arthropathy, and allowed the better monitoring of progressive joint damage, but further research into the underlying mechanisms of the disease is required to allow the development of more targeted treatment. In the meantime, patient management should be based on the risk factors for the onset and progression of arthropathy of each individual patient, and all patients should be collaboratively cared for by multidisciplinary teams of hematologists, rheumatologists, orthopedic surgeons, and physiotherapists at comprehensive hemophilia treatment centers.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Gualtierotti R, Solimeno LP, Peyvandi F, et al. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost. 2021. PMID: 34197690. doi:10.1111/jth.15444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。